LYCOS RETRIEVER 
The Millennium: Millennium Pharmaceuticals
built 223 days ago
The Millennium Group is a premier provider of facilitymanagement services focused on document management and office services. This includes traditional mail and reprographic (copy) services as well as distributed print, records and image management. The Millennium Group successfully services a broad base of industries from legal, pharmaceutical and financial services to education, healthcare, media, not-for-profit and government agencies.
Source:
CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM) today presented results of research on a new oncology molecule, MLN4924, a first-in-class, small molecule inhibitor of the Nedd 8 Activating Enzyme (NAE). NAE is a novel Millennium-discovered target in the protein homeostasis pathway. NAE acts upstream of the proteasome, the target of VELCADE(R) (bortezomib) for Injection, the Company's market-leading therapy for patients with previously treated multiple myeloma and mantle cell lymphoma. The data on NAE were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Source:
CAMBRIDGE, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) granted priority review for VELCADE in patients with newly diagnosed multiple myeloma (MM). The supplemental New Drug Application (sNDA) submitted to the FDA for this indication included data from the Phase III VISTA(1) study, a large, well-controlled international clinical trial, comparing a VELCADE based regimen to a traditional standard of care. VELCADE is the market-leader for MM and mantle cell lymphoma patients who have received at least one prior therapy.
Source:
Even better, Millennium has managed to collaborate with the big boys while not giving away its prized intellectual property. It has partnered while still working toward its ultimate goal of becoming an independent pharmaceutical company (see "Slow Growth"). And it has done this better than perhaps any other biotech company--a feat attributable both to the quality of the company's management team and to the new technologies that guide modern drug development. Millennium was in the right place, with the right people, at the right time.
Source:
VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and J&JPRD. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.
Source:
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.
Source:
MORE ABOUT
Millennium Pharmaceuticals